A foundation model company just paid $400 million in stock for a team of fewer than 10 people. The implications for drug discovery, precision medicine, and the entire healthcare AI landscape are enormous. On April 3, 2026, Anthropic confirmed the acquisition of Coefficient Bio, a stealth biotech AI startup, in an all-stock transaction valued at…
🔬 Epigenetic Reprogramming Enters Human Trials — The FDA cleared the first partial de-aging trial using OSK reprogramming factors, targeting vision restoration in glaucoma patients.
🧠 Diet and APOE Genetics Collide — Higher meat intake correlated with slower cognitive decline in older adults carrying Alzheimer's risk genes, upending common dietary assumptions.
🤖 NVIDIA and Lilly Bet $1 Billion on AI Drug Discovery — A landmark co-innovation lab in San Francisco will embed AI engineers alongside biologists to redesign how medicines are discovered.
🦠 Gut Bacteria Act Like Syringes — Common gut microbes can inject proteins directly into human cells, reshaping how researchers understand microbiome-immune crosstalk.
😴 Circadian Fragmentation Doubles Dementia Risk — Weak internal body clocks are now confirmed as a significant, and potentially modifiable, risk factor for dementia.
🧬 Cellular Reprogramming Enters Human Trials — Life Biosciences has launched the first FDA-approved partial de-aging trial, translating Sinclair's epigenetic reprogramming research from animal models to human medicine.
🧠 Gut-Brain Axis Reverses Memory Loss — Stanford's Nature study shows that correcting age-related gut bacteria shifts restores youthful cognitive performance by reactivating vagus nerve signaling to the hippocampus.
🤖 AI Drug Discovery Reaches Clinical Scale — 173+ AI-designed drug candidates are now in clinical trials, and longevity medicine is being advised to prepare for AI therapeutics to arrive in clinical practice imminently.
🦠 Gut Microbiome as Active Immune Regulator — New research reveals gut bacteria actively inject proteins into cells to modulate immunity, and a microbiome-derived molecule doubled lung cancer immunotherapy response rates in mice.
😴 Circadian Fragmentation Doubles Dementia Risk — A large Neurology journal study found that weak or late-peaking daily activity rhythms more than double the risk of dementia, making circadian optimization a key prevention target.
The FDA has cleared the first-ever human trial of epigenetic reprogramming longevity therapy, while an AI model published in Cell identifies new drug candidates at unprecedented speed. Together with a landmark Nature Aging study on epigenetic clocks, these breakthroughs signal that biological aging has become measurable, modifiable, and AI-acceleratable.
🔬 Aging is a coordination failure — The 2026 World Congress on Targeting Longevity is reframing aging as a breakdown between biological systems, shifting strategy from single-target drugs to systems medicine.
🤖 AI drug discovery hits clinical scale — Over 173 AI-discovered drug programs are now in human trials with breakthrough Phase I success rates, and new tools can screen millions of compounds in hours.
🫁 Aging lung cells drive respiratory vulnerability — UCSF researchers pinpointed aging fibroblasts as the trigger for the deadly inflammatory overreaction that makes flu and COVID so dangerous in older adults.
🦠 Gut bacteria directly control immunity — Microbes inject proteins into human cells to manipulate immune responses, a discovery that could lead to an entirely new category of microbiome therapies.
💪 Muscle power predicts survival better than strength — Mayo Clinic Proceedings research shows explosive muscle power has a nearly 7x mortality differential between lowest and highest performers in older women.
A landmark UK Biobank study of 60,977 people found that sleep regularity is a stronger predictor of mortality than sleep duration, reducing all-cause death risk by 30 percent. Combined with a 2026 OHSU population study and the American Heart Association’s new multidimensional sleep health framework, the evidence demands a fundamental shift in how we think about sleep and longevity. Here is what the research says and what you can do about it starting today.
David Sinclair helped make longevity science impossible to ignore. He also became one of its most contested public figures. Part II examines the criticism, contradictory evidence, and scientific arguments that define the battle over his legacy and the future of aging research.
The EVOKE and EVOKE+ trials of oral semaglutide in 3,808 Alzheimer’s patients failed their primary endpoints, but stunning biomarker data, positive liraglutide brain volume results, and consistent real-world evidence from over a million patients suggest GLP-1 receptor agonists may still hold the key to neuroprotection. Here is what the science actually shows and where the field goes next.
David Sinclair helped move aging research from the scientific margins into mainstream conversation. Through his Harvard lab, his work on sirtuins, NAD+ biology, epigenetic reprogramming, and his public role as a translator of longevity science, he helped make aging a serious biomedical frontier.
Harvard researcher Marinka Zitnik is building AI systems designed to uncover hidden treatments for rare and neglected diseases. Her TxGNN work points toward a future where drug repurposing becomes more systematic, more transparent, and more useful for patients medicine has historically overlooked.
Zach RobertsSign up for personalized wellness coaching and the Daily Discovery Newsletter.